KŪRYBOS TERAPIJOS NAMAI - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | - | 2,286 | 940 | 1,716 | 5,717 | 7,000 | 6,044 | 7,756 |
| Profit before tax | - | - | - | - | 415 | -560 | -7,151 | -1,096 |
| Net profit | - | - | - | - | 415 | -560 | -7,151 | -1,096 |
| Equity | 193 | 29 | 29 | -299 | 116 | -444 | -7,596 | -8,691 |
| Liabilities | 555 | 497 | 477 | 455 | 321 | 382 | 9,259 | 10,490 |
| Non-current assets | 0 | 0 | 560 | 343 | 127 | 1 | 1 | 1 |
| Current assets | 4,006 | 6,273 | 2,070 | -187 | 310 | -63 | 1,662 | 1,798 |
| Total assets | 4,006 | 6,273 | 2,630 | 156 | 437 | -62 | 1,663 | 1,799 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | - | - | 58 |
|
Financial indicators
|
||||||||
| Revenue change y/y | - | - | -58.9% | +82.6% | +233.2% | +22.4% | -13.7% | +28.3% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | - | - | - | - | 95.0% | - | -430.0% | -60.9% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | - | - | - | 357.8% | - | - | - |
| Profit margin Net profit margin. Shows the overall profitability of the company. | - | - | - | - | 7.3% | -8.0% | -118.3% | -14.1% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - | - | 7.3% | -8.0% | -118.3% | -14.1% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 2.9 | 17.1 | 16.4 | - | 2.8 | - | - | - |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | 2,286 | 940 | 1,716 | 5,717 | 7,000 | 6,044 | 7,756 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
KŪRYBOS TERAPIJOS NAMAI - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-02-18 | 2026-03-11 | 48.73 |
| 2025-03-18 | 2025-03-19 | 40.91 |
| 2025-01-02 | 2025-01-06 | 35.94 |
| 2024-12-22 | 2024-12-31 | 35.94 |
| 2024-12-17 | 2024-12-20 | 35.94 |
| 2024-06-18 | 2024-06-18 | 40.76 |
| 2024-02-19 | 2024-02-25 | 43.64 |
| 2023-11-16 | 2023-12-12 | 0.17 |
| 2023-10-30 | 2023-11-12 | 0.17 |
| 2023-10-25 | 2023-10-25 | 0.17 |
| 2023-07-18 | 2023-08-03 | 42.11 |
| 2023-02-06 | 2023-02-06 | 0.01 |
| 2023-01-17 | 2023-02-03 | 0.01 |
| 2022-12-16 | 2023-01-09 | 0.01 |
| 2022-10-31 | 2022-11-08 | 0.01 |
| 2022-09-21 | 2022-10-11 | 0.03 |
| 2022-09-16 | 2022-09-20 | 38.32 |
| 2022-08-23 | 2022-09-15 | 0.03 |
| 2022-06-16 | 2022-08-09 | 0.03 |
| 2022-05-17 | 2022-06-13 | 0.03 |
| 2022-04-25 | 2022-05-03 | 0.10 |
| 2022-04-19 | 2022-04-24 | 0.07 |
| 2022-03-16 | 2022-04-04 | 0.07 |
| 2022-02-18 | 2022-03-03 | 0.07 |
| 2022-02-17 | 2022-02-17 | 30.70 |
| 2022-01-18 | 2022-02-16 | 0.07 |
| 2021-12-16 | 2022-01-05 | 0.07 |
| 2021-11-16 | 2021-12-05 | 0.07 |
KŪRYBOS TERAPIJOS NAMAI - VMI tax arrears
As of 2026-09-02, the amount of overdue STI tax debt of the company KŪRYBOS TERAPIJOS NAMAI is: 0 €
| From | To | Overdue, € |
|---|---|---|
| 2026-02-27 | 2026-09-02 | 0.06 |
| 2026-02-21 | 2026-02-26 | 47.04 |
| 2025-02-20 | 2026-01-24 | 0.04 |
| 2024-03-01 | 2025-02-04 | 0.04 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
KURYBOS TERAPIJOS NAMAI, VšI is a Public Institution (code 302551756) operating in other education n.e.c. In 2025, the company generated revenue of €7.8K and recorded a net loss of €1.1K, equal to a profit margin of -14.1%. Revenue improved by 28.3% year on year and was also 10.8% higher over two years, showing a gradual recovery after a weaker 2024. Profitability remained under pressure: the 2023 loss was €560, the loss widened to €7.2K in 2024, and then narrowed again in 2025. The balance sheet remained weak, with total assets of €1.8K, equity of -€8.7K and liabilities of €10.5K at the end of 2025. Asset turnover was 4.31x, indicating revenue was generated from a very small asset base, while revenue per employee was €7.8K and profit per employee was -€1.1K. Overall, the 2025 results show higher sales, but the company still operated with negative equity and continued losses.